阿巴西普在严重镰状细胞病患儿无关供者干细胞移植中有效预防移植物抗宿主病
+100天II-IV级和III-IV级急性GVHD发生率分别为28.6%和7%,1年慢性GVHD发生率为57%,2年总生存率和无病生存率分别为100%和92.9%。
要点
- +100天II-IV级和III-IV级急性GVHD发生率分别为28.6%和7%。
- 1年慢性GVHD发生率为57%,除1例外均为轻度/局限型。
- 中位随访1.6年时,2年总生存率和无病生存率分别为100%和92.9%。
核心结论
- 尽管存在年龄较大、无关供者和HLA不合等风险因素,该减低强度预处理干细胞移植试验1期部分结果令人鼓舞,支持在临床试验 settings 中进一步评估无关供者干细胞移植。
- 该试验2期部分正在进行中。
研究设计与样本
- 1期多中心干细胞移植试验,纳入严重镰状细胞病患儿,供者来自HLA全合(n=7)或单抗原不合(n=7)无关供者,干细胞来源为骨髓或脐带血。
- 预处理方案包括远端阿仑单抗、氟达拉滨和美法仑(全合供者),不合供者加用塞替派。
- GVHD预防在他克莫司和甲氨蝶呤基础上加用阿巴西普(选择性T细胞共刺激抑制剂),骨髓受者接受阿巴西普时间较脐带血受者更长。
- 移植时中位年龄为13岁(范围7-21岁)。
主要发现
- +100天时II-IV级急性GVHD发生率为28.6%,III-IV级急性GVHD发生率为7%。
- 1年慢性GVHD发生率为57%,除1例接受较长疗程阿巴西普的患者外均为轻度/局限型。
- 仅1例患者发生可逆性后部脑病综合征并恢复。
- 中位随访1.6年(范围1-5.5年),2年总生存率为100%,无病生存率为92.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report results of a phase 1 multicenter stem cell transplantation (SCT) trial from HLA-matched (n = 7) or one-antigen-mismatched (n = 7) unrelated donors (URD) using bone marrow or cord blood as stem cell source, following reduced-intensity conditioning (RIC) in severe sickle cell disease (SCD). Conditioning included distal alemtuzumab, fludarabine, and melphalan (matched donors), with thiotepa (mismatched donors). Abatacept, a selective inhibitor of T cell costimulation, was added to tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis to offset GVHD risks, and was administered for longer duration in bone marrow recipients than in cord blood recipients because of increased incidence of chronic GVHD with bone marrow. Median age at transplant was 13 years (range, 7-21 years). The incidence of grades II to IV and grades III to IV acute GVHD at day +100 was 28.6% and 7%, respectively. One-year incidence of chronic GVHD was 57% and mild/limited in all but 1 patient who received abatacept for a longer duration. Only 1 patient developed reversible posterior encephalopathy syndrome and recovered. With a median follow-up of 1.6 years (range, 1-5.5 years), the 2-year overall and disease-free survival was 100% and 92.9%, respectively. The encouraging results from the phase 1 portion of this RIC SCT trial, despite risk factors such as older age, URD, and HLA-mismatch, support further evaluation of URD SCT in clinical trial settings. The phase 2 portion of the trial is in progress. This trial was registered at www.clinicaltrials.gov as NCT03128996.
引用
- Ngwube A, Shah N, Godder K, et al. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Adv. 2020. PMID: 32813873. doi:10.1182/bloodadvances.2020002236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。